반응형

FDA 72

[Emergo, UL] IMDRF Releases Key Guidance Documents for Medical Device Software

The International Medical Device Regulators Forum (IMDRF) released two key documents related to medical device software: Good machine learning practice for medical device development: Guiding principles (IMDRF/AIML WG/N88 FINAL:2025); and Characterization Considerations for Medical Device Software and Software-Specific Risk (IMDRF/SaMD WG/N81 FINAL:2025). These documents are aimed at improving g..

뉴스 보고서 2025.02.06

[Emergo, UL] US FDA Rules for Notification of Discontinuation or Meaningful Interruption in Manufacturing

This month, the U.S. Food and Drug Administration (FDA), finalized guidance requiring manufacturers to notify them of discontinuations or meaningful interruptions in manufacturing for many devices during or in advance of a public health emergency (PHE). This relatively new authority was established through the 2020 CARES Act and amended by the 2023 Omnibus Consolidated Appropriations Act, alteri..

뉴스 보고서 2025.02.04

[Emergo, UL] Webinar: Determining when to utilize the Pre-Submissions Q-Submission (Pre-Sub) Process

Emergo에서 아래와 같이 웨비나를 개최한다.​▶ 주제: Determining when to utilize the pre-submissions Q-submission (Pre-Sub) Process▶ 일시: 2025년 02월 12일 CST 9시 (한국시간: 02월 13일 00시) In many cases, a manufacturer must submit a marketing submission (such as a 510(k)) to the U.S. Food and Drug Administration (FDA) and have it authorized before they can start selling that device in the U.S. But what if a manufacturer has q..

[US, FDA] Medical Device Sterilization Town Hall: Sterilization Short Topics, Series Impact, Wrap Up, and Next Steps

SummaryOn December 4, 2024 the U.S Food and Drug Administration (FDA) held a Medical Device Sterilization Town Hall: Sterilization Short Topics, Series Impact, Wrap Up, and Next Steps.During this town hall, we discussed two short topics, including the new Transitional Enforcement Policy for Ethylene Oxide Sterilization Facility Changes for Class III Devices Guidance, and research and modeling on..

미국 FDA 2024.12.30

[US, FDA] Artificial Intelligence and Machine Learning (AI/ML)-Enabled Medical Devices

The FDA encourages the development of innovative, safe, and effective medical devices, including devices that incorporate Artificial Intelligence and Machine Learning (AI/ML).  The AI/ML-Enabled Medical Device List is a resource intended to identify AI/ML-enabled medical devices that are authorized for marketing in the United States (updated).  Artificial Intelligence and Machine Learning (AI/ML..

미국 FDA 2024.12.27

[US, FDA] Clinical Decision Support Software Frequently Asked Questions (FAQs)

Clinical Decision Support (CDS) software are important tools in modern health care. While some CDS software has been excluded from the definition of a medical device by the 21st Century Cures Act (Cures Act), many software functions continue to meet the definition of a medical device and are the focus of the Food and Drug Administration’s (FDA) regulatory oversight. Because a wide variety of sof..

미국 FDA 2024.12.24

[Emergo, UL] What Does it Mean for a Device to be Inherently Safe by Design?

Both the FDA’s Human Factors Engineering (HFE) guidance and the global HFE standard IEC-62366 list “inherent safety by design” as the most effective method of managing use-related risks associated with medical devices. In this article, we discuss what is meant by safety by design, provide examples of products that demonstrate it and explore how it can be implemented within medical device design...

뉴스 보고서 2024.12.18

[Emergo, UL] When to Verify Risk Control Measures as Part of Human Factors Engineering Activities

We all know the chicken or the egg causality dilemma, often introduced as “what came first, the chicken or the egg?” You could pose a similar question for risk control measures referenced in HF validation tests: What comes first, the verification of use-related risk control measures or the HF validation test?   When to Verify Risk Control Measures | Emergo by UL When to Verify Risk Control Measu..

뉴스 보고서 2024.12.16

[US, FDA] Transitional Enforcement Policy for Ethylene Oxide Sterilization Facility Changes for Class III Devices

FDA is issuing this guidance to communicate its policy regarding sterilization site changes for ethylene oxide (EtO) sterilized PMA and HDE devices in situations where those devices are affected by the potential, actual, or temporary operation reductions at sterilization facilities that may affect the availability of those sterile medical devices. FDA does not intend to object to sterilization o..

미국 FDA 2024.12.10
반응형